NAL Pharmaceuticals   Report issue

For profit Phase 4
Founded: Hong Kong Hong Kong (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2015
NCT02271919
First Marketed Drug
2021
lidocaine (xylocaine)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NAL PHARM

Active Ingredients

Marketed Drugs (1)

lidocaine (xylocaine) (2021)

Drugs in Phase 4 Trials (2)

nicotine (nicorette) (2 trials)

varenicline (chantix) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 4)

Tobacco Use Disorder (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2